(Albendazole 400 mg)


Each SENNAZOLE tablet contains Albendazole 400mg which is a benzimidazole carbamate antihelmintic structurally related to mebendazole  and is similarly active against most nematode and some other worms. SENNAZOLE is used in the treatment of single and mixed intestinal nematode infections including ascariasis, enterobiasis, hookworm, and trichuriasis. It is preferred to mebendazole in strongyloidiasis as mebendazole is less effective against migrating larvae. It is also used in the treatment of capillariasis. SENNAZOLE may also be effective in the treatment of the tissue nematode infections cutaneous larva migrans, toxocariasis, and trichinosis. In the cestode infections cysticercosis and echinococcosis (hydatid disease), SENNAZOLE has largely replaced mebendazole. SENNAZOLE is sometimes used in opisthorchiasis.  Beneficial responses have been reported in a few patients with the protozoal infection microsporidiosis .


SENNAZOLE is poorly absorbed from the gastro-intestinal tract, but rapidly undergoes extensive first-pass metabolism. The principal metabolite Albendazole sulphoxide has antihelmintic activity and a plasma half-life of about 8.5 hours. Albendazole sulphoxide is excreted in the urine together with other metabolites including Albendazole sulphone and the 2-amino sulphoxide and 2-amino sulphone.

Albendazole appears to be metabolised extremely rapidly since it cannot be detected in plasma. Plasma concentrations of the active metabolite Albendazole sulphoxide are extremely variable between individuals, probably because of variable absorption. No correlation was found between maximum plasma concentrations after the initial loading dose and minimum concentrations at steady state during maintenance therapy. SENNAZOLE partially inhibits microsomal enzyme function but induces its own metabolism, and suggests that cyclic therapy could be more effective than continuous therapy. Binding of Albendazole sulphoxide to plasma protein has been noted to be about 70%. The major urinary metabolite is Albendazole sulphoxide. The total dose of SENNAZOLE is excreted as the sulphoxide over 24 hours.


Although generally well-tolerated, the following adverse  reactions were reported in the first phase of WHO-coordinated studies  given high-dose therapy with  Albendazole for the treatment of cystic echinococcosis  (hydatid disease) : raised serum-transaminase levels , reduced leukocyte counts , gastro-intestinal  symptoms, allergic conditions , and  loss of hair . 


SENNAZOLE is given by mouth, usually as a single dose, in the treatment of single or mixed intestinal nematode infections. The usual dose for adults and children aged 2years or over with ascariasis, hookworm infections, ortrichuriasis is 400 mg as a single dose. In enterobiasis the dose may be repeated in 1 to 3 weeks. Some sources suggest that the dose in children over 2 years with enterobiasis could be reduced to 100 mg. In strongyloidiasis, 400 mg is given daily for 3 consecutive days; this may be repeated after 3 weeks if necessary. A dose of 200 mg twice daily for 10 days or more has been suggested in capillariasis. In the treatment of echinococcosis, SENNAZOLE is given in a dose of 10 to 15mg per kg body-weight daily (or 800 mg daily in patients weighing over 60 kg) for a month. If it is being given before surgery, then the patient is given a second course after a 2-week treatment-free period. Where surgery is not possible ,and if the infection is with Echinococcus granulosus, then the patient is given another 2 or 3 courses (making 3 or 4 courses in total) with the same 2-week period between them. If the infection is with E. multilocularis then the courses might have to be repeated for a year or more.


SENNAZOLE is available as :

*           A Single Dose Blister of One Tablet

            Each Tablet contains : Albendazole USP 400mg